AVXL · Company research
Anavex Life Sciences (AVXL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
31records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| ROSEN, RECOGNIZED TRIAL ATTORNEYS, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs. | View source ↗ | GlobeNewswire Inc. | Oct 18, 2026 | bearish | -1 | 1 |
| The FDA lets Anavex (AVXL) test an investigational drug for Fragile X syndrome. - Stock Titan | The FDA lets Anavex (AVXL) test an investigational drug for Fragile X syndrome. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Fragile X has no FDA-approved treatment. Anavex plans a study in about 60 adult men. - Stock Titan | Fragile X has no FDA-approved treatment. Anavex plans a study in about 60 adult men. Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| AVXL Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corp. Class Action Lawsuit | Robbins LLP announced a class action lawsuit against Anavex Life Sciences Corp. for allegedly misleading investors about inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased AVXL securities between November 26, 2025 and August 28, 2026. The lead plaintiff deadline is November 30, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented the company's business and prospects. The lead plaintiff deadline is November 30, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented the company's business and prospects. The lead plaintiff deadline is November 30, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | bearish | -1 | 1 |
| AVXL INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Anavex Life Sciences Corp. Shareholders | Kirby McInerney LLP has filed securities fraud class action lawsuits against Anavex Life Sciences Corp. for allegedly making false statements and failing to disclose inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased securities between November 26, 2025 and August 28, 2026. Anavex's stock declined significantly following disclosures about the CEO's termination, delayed SEC filings, and material weaknesses in internal controls. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bearish | -1 | 1 |
| AVXL INVESTORS: Contact Kirby McInerney LLP About the Securities Fraud Lawsuit Filed on Behalf of Anavex Life Sciences Corp. Shareholders | Kirby McInerney LLP has filed securities fraud class action lawsuits against Anavex Life Sciences Corp. for allegedly making false statements and failing to disclose inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased securities between November 26, 2025 and August 28, 2026. Anavex's stock declined significantly following disclosures about the CEO's termination, delayed SEC filings, and material weaknesses in internal controls. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bearish | -1 | 1 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Tigo Energy, Inc. (TYGO), Fluence Energy, Inc. (FLNC), and Anavex Life Sciences Corp. (AVXL) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits. Tigo Energy faces allegations of false statements regarding an EG4 Electronics partnership (deadline: November 23, 2026). Fluence Energy is accused of misleading statements about production capabilities and revenue guidance (deadline: November 30, 2026). Anavex Life Sciences faces allegations of inadequate internal controls and understated regulatory challenges related to former CEO misconduct (deadline: November 30, 2026). | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Tigo Energy, Inc. (TYGO), Fluence Energy, Inc. (FLNC), and Anavex Life Sciences Corp. (AVXL) Announced by Holzer & Holzer, LLC | Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits. Tigo Energy faces allegations of false statements regarding an EG4 Electronics partnership (deadline: November 23, 2026). Fluence Energy is accused of misleading statements about production capabilities and revenue guidance (deadline: November 30, 2026). Anavex Life Sciences faces allegations of inadequate internal controls and understated regulatory challenges related to former CEO misconduct (deadline: November 30, 2026). | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN | Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. and Anavex Life Sciences Corp. on behalf of investors who purchased securities during specified periods. The Qfin lawsuit alleges defendants made false statements about business resilience and downplayed regulatory impacts. Investors have until November 30, 2026 to move the court to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Qfin Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QFIN | Rosen Law Firm has filed class action lawsuits against Qfin Holdings, Inc. and Anavex Life Sciences Corp. on behalf of investors who purchased securities during specified periods. The Qfin lawsuit alleges defendants made false statements about business resilience and downplayed regulatory impacts. Investors have until November 30, 2026 to move the court to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ANAVEX CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Anavex Life Sciences Corp. and Encourages Investors to Contact the Firm | A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and its executives violated federal securities laws by making false and misleading statements regarding adequate internal controls, understating regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresenting the company's business and prospects. Investors who purchased Anavex securities between November 26, 2025 and August 28, 2026 may be eligible to participate in the lawsuit. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bearish | -1 | 1 |
| ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that the company made false and misleading statements regarding adequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| ROSEN, THE FIRST FILING FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXL | Rosen Law Firm has filed a class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that the company made false and misleading statements regarding adequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented its business operations and prospects. Investors have until November 30, 2026 to move the court to serve as lead plaintiff. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Anavex Life Sciences Corp. alleging securities fraud. The complaint claims the company made false statements about its business operations, lacked adequate internal controls, and understated regulatory challenges related to misconduct by former CEO Christopher Missling. The class period covers November 26, 2025 to August 28, 2026, and investors have until November 30, 2026 to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| Bronstein, Gewirtz & Grossman LLC Urges Anavex Life Sciences Corp. Investors to Act: Class Action Filed Alleging Investor Harm | A class action lawsuit has been filed against Anavex Life Sciences Corp. alleging securities fraud. The complaint claims the company made false statements about its business operations, lacked adequate internal controls, and understated regulatory challenges related to misconduct by former CEO Christopher Missling. The class period covers November 26, 2025 to August 28, 2026, and investors have until November 30, 2026 to request lead plaintiff status. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bearish | -1 | 1 |
| Anavex Shareholders Back Board Slate in Contested Meeting - The Globe and Mail | Anavex Shareholders Back Board Slate in Contested Meeting The Globe and Mail | View source ↗ | The Globe and Mail | Sep 29, 2026 | neutral | 0 | 0.6 |
| A board election triggered a “change in control” at Anavex (AVXL), making its treasurer's options exercisable. - Stock Titan | A board election triggered a “change in control” at Anavex (AVXL), making its treasurer's options exercisable. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance - Yahoo Finance | PVG Asset Management Believes ISS Acknowledges Anavex’s Repeated Missteps, Failed Board Oversight, Lack of Director Stock Ownership, and AVXL Stock Price Underperformance Yahoo Finance | View source ↗ | Yahoo Finance | Sep 14, 2026 | neutral | 0 | 0.6 |
| Anavex will keep trading on Nasdaq after filing its outstanding reports - Stock Titan | Anavex will keep trading on Nasdaq after filing its outstanding reports Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| Anavex: After The EU Said No, The FDA Path Looks Long And Expensive - Seeking Alpha | Anavex: After The EU Said No, The FDA Path Looks Long And Expensive Seeking Alpha | View source ↗ | Seeking Alpha | Aug 26, 2026 | neutral | 0 | 0.6 |
| Anavex submits Alzheimer’s data as Fragile X filing is expected in September - Stock Titan | Anavex submits Alzheimer’s data as Fragile X filing is expected in September Stock Titan | View source ↗ | Stock Titan | Aug 25, 2026 | neutral | 0 | 0.6 |
| Six Anavex Director Nominees Face a Sept. 24 Vote—What Sets Them Apart? - Stock Titan | Six Anavex Director Nominees Face a Sept. 24 Vote—What Sets Them Apart? Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| Anavex reports $5.3 million preliminary Q2 net loss - Quiver Quantitative | Anavex reports $5.3 million preliminary Q2 net loss Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 30, 2026 | neutral | 0 | 0.6 |
| AVXL Forecast — Price Target — Prediction for 2027 - TradingView | AVXL Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 29, 2026 | neutral | 0 | 0.6 |
| What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks - Yahoo Finance | What Makes Anavex Life Sciences (AVXL) One of the Best Shorted Penny Stocks Yahoo Finance | View source ↗ | Yahoo Finance | Apr 26, 2026 | neutral | 0 | 0.6 |
| Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? - Yahoo Finance | Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip? Yahoo Finance | View source ↗ | Yahoo Finance | Mar 26, 2026 | neutral | 0 | 0.6 |
| EU review halts Anavex’s Alzheimer’s drug bid, more data next - Stock Titan | EU review halts Anavex’s Alzheimer’s drug bid, more data next Stock Titan | View source ↗ | Stock Titan | Mar 25, 2026 | neutral | 0 | 0.6 |
| AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug - Stocktwits | AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug Stocktwits | View source ↗ | Stocktwits | Mar 5, 2026 | neutral | 0 | 0.6 |
| Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - Anavex Life Sciences | Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update Anavex Life Sciences | View source ↗ | Anavex Life Sciences | Nov 25, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.